When it comes to growth investing, companies operating in trendy industries are among the most popular stock choices among investors. As a result, the majority of long-term investors overlook many utilitarian, small-cap companies. This scenario is a positive for investors seeking value along with growth, as it often means great growth at cheaper valuations.
Perhaps no industry is more overlooked than the chemicals space. The primary reason is that the industry creates products designed to operate behind the scenes and out of the public's purview.
Balchem (BCPC 0.54%) and Stepan (SCL -1.04%) are two of the best long-term investments in the space; both offer great growth, solid dividend performance and currently trade at relatively cheap valuation multiples.
While Balchem's and Stepan's chemical businesses may be boring, the growth both companies have been churning out is anything but. In fact, Balchem and Stepan are expected to continue to grow at robust rates going forward. The following is a breakdown of the companies' projected growth in 2014 compared to industry behemoth Dow Chemical (DOW):
|Company||Revenue Growth||EPS Growth|
Both Balchem and Stepan are projected to grow sales in 2014 at much faster rates than larger peer Dow Chemical. Even though Balchem is expected to lag both competitors in the earnings-per-share category, 15.9% growth in EPS is still admirable.
Additionally, considering the above-average growth, forward-looking valuation multiples for Balchem and Stepan are not too expensive. Balchem's forward P/E of 24.8 and Stepan's forward P/E of 12.1 are lower than many popular growth stocks growing at comparable levels.
Perhaps most impressive is that despite superior growth all around, Stepan's forward P/E of 12.2 is still cheaper than Dow Chemical's 14.1.
For Balchem, continued success in its animal nutrition and health department is important. The company's latest expanded alliance with Versus Animal Nutrition assures this. Versus, formerly a supplier to Western Canada only, is now teaming up with Balchem to offer the company's animal nutrient and mineral solutions to all parts of Canada, which vastly expands the company's business in the region.
Additionally, Balchem recently announced an agreement with Taminco to construct and operate a choline chloride facility in Louisiana. Together, Balchem and Taminco will invest to build the facility into a large scale producer of choline chloride, servicing consumers around the world. The facility is expected to go online in 2015.
On the other hand, Stepan's growth in 2014 is expected to come primarily from improving economic conditions around the world as well as positive trends in the company's main consumer markets. Continued global growth in polypol, which is used as energy saving insulant in foam installation, is expected to add significant volume growth in Stepan's polymer segment.
Additionally, the company's latest acquisition of Bayer's North American polyester resin business is now fully integrated and is set to contribute a full year of operation under Stepan control.
On continued international expansion, President and CEO F. Quinn Stepan Jr, explained, "We plan to build a new plant in China to participate [in] what we expect will become the largest polyol market in the world. Overall, the health of our balance sheet remains strong and will facilitate investments in growth and efficiency opportunities. And that will deliver value to you, our shareholders."
Also worth noting are both companies' impressive track record of paying dividends to investors. Balchem is especially impressive in this regard. Although the company only pays a dividend of $0.26, equal to a yield of 0.50%, Balchem has raised its dividend every year in the last decade and has averaged annual dividend growth of 34.3% in that time.
Stepan's dividend of $0.68, equal to a yield of 1.10%, is more substantial. However, despite consistently raising its dividend each year, the company has only averaged annual dividend growth of 5.5% in the last decade.
Flashy companies in trendy industries are not investors' only options for growth. Often times, the smaller and lesser-known companies are better alternatives, particularly because they usually carry significantly less headline risk.
Balchem and Stepan are perfect examples of the benefits of boring but beautiful growth companies. With practical and reliable business mixes, both companies look like viable long-term investments currently trading at value prices.